Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

[Monoclonal antibodies for anti-infective therapy].

Tytuł:
[Monoclonal antibodies for anti-infective therapy].
Autorzy:
Klug B; Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland. .
Schnierle B; Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225, Langen, Deutschland.
Trebesch I; Robert Koch-Institut, Berlin, Deutschland.
Transliterated Title:
Monoklonale Antikörper zur antiinfektiven Therapie.
Źródło:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz [Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz] 2020 Nov; Vol. 63 (11), pp. 1396-1402. Date of Electronic Publication: 2020 Oct 09.
Typ publikacji:
Journal Article; Review
Język:
German
Imprint Name(s):
Original Publication: Berlin : Springer,
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Coronavirus Infections*
Pandemics*
Pneumonia, Viral*
Animals ; Antibodies, Viral ; Betacoronavirus ; COVID-19 ; Germany ; Humans ; SARS-CoV-2
References:
Arthritis Rheum. 2013 Oct;65(10 Suppl):S1-1331. (PMID: 24085684)
Nature. 1975 Aug 7;256(5517):495-7. (PMID: 1172191)
Emerg Microbes Infect. 2019;8(1):516-530. (PMID: 30938227)
NPJ Vaccines. 2017 Jul 10;2:19. (PMID: 29263875)
PLoS Med. 2006 Jul;3(7):e237. (PMID: 16796401)
Nature. 1998 Jun 18;393(6686):648-59. (PMID: 9641677)
Arch Pharm Res. 2015;38(5):575-84. (PMID: 25648633)
Dtsch Med Wochenschr. 1965 Dec 3;90(49):2183. (PMID: 5843503)
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134)
Bull World Health Organ. 2017 Mar 1;95(3):235-237. (PMID: 28250538)
J Transl Med. 2020 Apr 14;18(1):164. (PMID: 32290839)
Immunol Today. 1992 May;13(5):188-90. (PMID: 1642758)
Drugs. 2019 Feb;79(3):347-352. (PMID: 30767127)
Antibodies (Basel). 2018 Jan 04;7(1):. (PMID: 31544858)
Oncology. 2020;98(3):131-137. (PMID: 31958792)
Clin Infect Dis. 2015 Feb 15;60(4):586-95. (PMID: 25433014)
Curr Opin HIV AIDS. 2015 May;10(3):129-34. (PMID: 25760933)
Int J Antimicrob Agents. 2020 May;55(5):105954. (PMID: 32234467)
Drugs. 2019 Nov;79(16):1741-1755. (PMID: 31486005)
PLoS One. 2009 May 22;4(5):e5672. (PMID: 19478856)
N Biotechnol. 2011 Sep;28(5):489-501. (PMID: 21473942)
Nat Commun. 2020 May 4;11(1):2251. (PMID: 32366817)
Drugs. 2018 Jun;78(9):929-940. (PMID: 29931592)
Emerg Microbes Infect. 2015 May;4(5):e28. (PMID: 26060601)
Drug Des Devel Ther. 2017 May 24;11:1593-1603. (PMID: 28579757)
Blood. 2019 Nov 21;134(21):1783-1786. (PMID: 31537529)
Respirology. 2006 Nov;11(6):715-22. (PMID: 17052299)
Toxins (Basel). 2012 Jun;4(6):430-54. (PMID: 22822456)
Clin Microbiol Infect. 2019 Jan;25(1):60-64. (PMID: 29715552)
Arthritis Res Ther. 2019 Apr 18;21(1):101. (PMID: 30999929)
Fukushima J Med Sci. 2017 Dec 19;63(3):127-134. (PMID: 28867684)
mBio. 2018 Oct 9;9(5):. (PMID: 30301856)
J Korean Med Sci. 2016 Nov;31(11):1717-1725. (PMID: 27709848)
Nephron. 1987;46 Suppl 1:41-7. (PMID: 3306424)
Clin Immunol. 2020 Jul;216:108442. (PMID: 32335290)
Vaccine. 2009 Dec 30;27 Suppl 6:G38-46. (PMID: 20006139)
Nat Med. 1999 Feb;5(2):211-6. (PMID: 9930870)
Patient Relat Outcome Meas. 2018 Jan 12;9:35-41. (PMID: 29391839)
N Engl J Med. 2019 Dec 12;381(24):2293-2303. (PMID: 31774950)
Expert Opin Ther Targets. 2014 Jun;18(6):703-14. (PMID: 24670033)
MAbs. 2010 Jan-Feb;2(1):3-13. (PMID: 20065636)
J Med Virol. 2019 Apr;91(4):588-597. (PMID: 30431664)
Science. 1979 Oct 19;206(4416):347-9. (PMID: 314668)
Ther Adv Hematol. 2019 Sep 10;10:2040620719874728. (PMID: 31534662)
Nat Med. 2008 Dec;14(12):1357-62. (PMID: 19029986)
Lancet. 2020 Mar 28;395(10229):1033-1034. (PMID: 32192578)
J Med Virol. 2020 Oct;92(10):1791-1792. (PMID: 32314799)
Contributed Indexing:
Keywords: Anti-bacterial monoclonal antibodie; Anti-viral monoclonal antibodies; Immunetherapy; SARS-CoV-2; Symptomatic treatment
Substance Nomenclature:
0 (Antibodies, Monoclonal)
0 (Antibodies, Viral)
Entry Date(s):
Date Created: 20201009 Date Completed: 20201110 Latest Revision: 20210110
Update Code:
20240105
PubMed Central ID:
PMC7545799
DOI:
10.1007/s00103-020-03229-1
PMID:
33034695
Czasopismo naukowe
Sera of animal origin and hyperimmunoglobulins have dominated serum therapy for a century. Although numerous monoclonal antibodies (MABs) have been developed since the end of the 1980s, particularly for the treatment of immunological and oncological diseases, it will take 20 years before the first anti-infective MAB is approved in the European Union. Interestingly, to combat the COVID-19 pandemic, numerous MABs, which are approved in particular for immunological indications, are currently being used to treat the consequences of SARS-CoV‑2 infection, such as pneumonia or hyperimmune reactions.The approved monoclonal antibodies for the treatment of infectious diseases are presented here. In addition, an overview of the current developments, in particular in the treatment of SARS-CoV‑2 infection, is provided.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies